Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL)

Historical Holders from Q2 2020 to Q3 2025

Symbol
ZNTL on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
64.7M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
52.8M
Holdings value
$79.7M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
97
Number of buys
40
Number of sells
-54
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Walters William T 9.9% +8.89% $10.1M $787K 7.05M +8.46% Walters William T 29 Jan 2025
Matrix Capital Management Company, LP 9.98% $9.69M 6.46M Matrix Capital Management Company, LP 15 Dec 2025
BARCLAYS PLC 5.32% $5.8M 3.84M Barclays PLC 30 Sep 2025
VANGUARD GROUP INC 4.59% $4.68M 3.27M The Vanguard Group 31 Dec 2024
BlackRock, Inc. 2.2% $1.95M 1.61M BlackRock, Inc. 30 Jun 2025
MILLENNIUM MANAGEMENT LLC 1.3% -80% $1.27M -$4.06M 903K -76.1% Millennium Management LLC 30 Sep 2025
FMR LLC 0.2% $251K 176K FMR LLC 29 Nov 2024

Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 52.8M $79.7M -$3.99M $1.51 97
2025 Q2 55.7M $64.6M -$4.21M $1.16 115
2025 Q1 58.5M $92.9M -$20.5M $1.59 131
2024 Q4 64.4M $195M -$24.7M $3.03 141
2024 Q3 71M $261M -$21.6M $3.68 133
2024 Q2 76.6M $313M -$54.4M $4.09 142
2024 Q1 85.3M $1.34B +$67M $15.76 140
2023 Q4 81.1M $1.23B -$22M $15.15 118
2023 Q3 80.2M $1.61B -$51.6M $20.06 136
2023 Q2 82.2M $2.32B +$443M $28.21 131
2023 Q1 67M $1.15B +$44.9M $17.20 108
2022 Q4 64.4M $1.3B +$105M $20.14 106
2022 Q3 58.8M $1.27B -$54M $21.66 116
2022 Q2 58.3M $1.64B +$359M $28.10 115
2022 Q1 44.4M $2.05B +$49.1M $46.14 123
2021 Q4 43M $3.61B +$90M $84.06 134
2021 Q3 41.3M $2.75B +$115M $66.64 114
2021 Q2 39.7M $2.11B +$206M $53.20 117
2021 Q1 36.3M $1.58B -$56M $43.39 93
2020 Q4 37.3M $1.94B +$310M $51.94 104
2020 Q3 31.6M $1.03B +$170M $32.69 65
2020 Q2 26.9M $1.28B +$1.28B $48.02 61